| Literature DB >> 24887260 |
Ann Green1, Virginia de Azevedo2, Gabriela Patten3, Mary-Ann Davies1, Mary Ibeto3, Vivian Cox3.
Abstract
INTRODUCTION: To combat the AIDS epidemic and increase HIV treatment access, the South African government implemented a nurse-based, doctor-supported model of care that decentralizes administration of antiretroviral treatment (ART) for HIV positive patients through nurse initiated and managed ART. Médecins Sans Frontières (MSF) implemented a mentorship programme to ensure successful task-shifting, subsequently assessing the quality of clinical care provided by nurses.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24887260 PMCID: PMC4041881 DOI: 10.1371/journal.pone.0098389
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1NIMART Clinical Mentorship Model for Integrated Services.
Pre-NIMART: PALSA Plus HIV course training on use South Africa's approved algorithmic tool for diagnosis and treatment of common opportunistic infections; A1: NIMART training based on South African Ministry of Health guidelines; A2: Authorization to initiate is granted based on three required criteria: completion of basic HIV course, PALSA Plus HIV training, and 40 hours of one-on-one mentorship; B: Basic End Point is reached whereby the authorized nurses is conducting independent initiations; C: Advanced End Point is reached when skill level is expanded to include management of paediatric patients, virologic failure, and drug-resistant TB.
Figure 2Sample selection flow diagram.
Quality of Nurse ART Management in Khayelitsha Clinics n = 80 patient clinical folders reviewed.
| Indicator | Before | % | After | % | p-value |
| ART date recorded | 80 | 100 | 79 | 98.8 | 0.316 |
| Last viral load>400 | 4/54 | 7.41 | 3/65 | 4.6 | 0.519 |
| Treatment plan documented for patients with viral load >400 | 2/4 | 50 | 1/3 | 33.3 | 0.659 |
| Creatinine clearance recorded | 13/74 | 17.56 | 10/65 | 15.4 | 0.73 |
| Documented result of most recent bloods | 74 | 92.5 | 75 | 93.8 | 0.755 |
| Last required bloods drawn | 73 | 91.25 | 79 | 98.8 |
|
| TB screen done | 63/76 | 82.89 | 68/74 | 91.9 | 0.098 |
| STI screen done | 71 | 88.75 | 75 | 93.8 | 0.263 |
| Family planning offered | 33/56 | 58.93 | 37/55 | 67.3 | 0.362 |
| Pap smear recorded /referenced | 4/60 | 6.67 | 6/57 | 10.5 | 0.455 |
| Clinical presentation entered | 80 | 100 | 80 | 100 | |
| Problem list entered | 33 | 41.25 | 36 | 45 | 0.632 |
| Adherence assessed and documented | 40 | 50 | 62 | 77.5 |
|
| Stage entered | 50 | 62.5 | 73 | 91.3 |
|
| Stage correlates with known medical history | 45 | 88 | 58 | 79.5 | 0.119 |
| Treatment plan documented | 58 | 72.5 | 66 | 82.5 | 0.13 |
| Referred to doctor | 1 | 1.25 | 2 | 2.5 | 0.56 |
| Medication entered | 80 | 100 | 80 | 100 | |
| ARV dose entered correctly | 64 | 80 | 64 | 80 | |
| Cotrimoxazole prescribed | 12 | 15 | 8 | 10 | 0.339 |
| Should Cotrimoxazole have been prescribed | 21 | 26.25 | 15 | 18.8 | 0.256 |
*Number of patients where particular indicator is applicable.
Quality of Nurse ART Initiations in Khayelitsha Clinics n = 80.
| Number recorded | % | |
| Patient weight documented | 76 |
|
| Patient BMI documented | 60 | 75 |
| Past medical history documented | 73 | 91.3 |
| Prior ART/history documented | 73 | 91.3 |
| If yes, was patient discussed with doctor | 0 | |
| Documented as ‘No ART history’ | 33 | 41.3 |
| Baseline CD4 documented | 80 |
|
| Creatinine documented | 79 |
|
| Creatinine clearance (CrCl) documented | 43 | 53.8 |
| IfCrCl<50, was patient discussed with doctor | 0 | |
| Not applicable | 77 | 41.3 |
| IfCrCl<50 and discussed by doctor, treatment documented | 0 | |
| Haemoglobin documented | 78 |
|
| Alanine aminotransferase (ALT) documented | 70 | 87.5 |
| IfALT>100, was patient referred to doctor | 0 | |
| ART initiation date recorded | 80 |
|
| TB screen done | 61 | 76.3 |
| On treatment | 17 | 21.3 |
| Investigation pending | 1 | 1.3 |
| STI screen done | 76 |
|
| Eligible for family planning | 59 | 73.8 |
| Family planning offered | 42 | 71.2 |
| Eligible for pap smear | 59 | 73.8 |
| Pap smear date recorded or referenced | 8 | 13.6 |
| Clinical presentation entered | 80 |
|
| Problem list entered | 62 | 77.5 |
| Stage entered | 80 |
|
| Stage correlates with known medical history | 80 |
|
| Treatment plan entered | 74 | 92.5 |
| Was patient seen or discussed with doctor in prior month | 19 | 23.8 |
| Medication entered | 80 |
|
| ARV dose entered correctly | 66 | 82.5 |
| Should Cotrimoxazole have been prescribed | 41 | 51.3 |
| Cotrimoxazole prescribed | 30 | 37.5 |
| Return date documented | 79 |
|
Patient Characteristics n = 80 n = 69.
| Nurse | Doctor | p-value | |
| Age (median) | 28 (IQR 24–35) | 31 (IQR 24–39) | 0.5654 |
| Gender | 0.352 | ||
| Male | 20 (25%) | 22 (28%) | |
| Female | 60 (75%) | 47 (62%) | |
| Weight (median) | 66 (IQR 61–78) | 59 (IQR 52–70) |
|
| Weight not recorded | 3 | 0 | |
| Infants | 0 | 2 | |
| BMI (median) | 26 (IQR 23–31) | 22 (IQR 19–26) |
|
| Weight not recorded | 3 | 0 | |
| BMI not recorded | 19 | 25 | |
| Infants | 0 | 2 | |
| Creatinine (median) | 62 (IQR 50–73) | 66 (IQR 51–81) | 0.2161 |
| missing | 1 | 2 | |
| Creatinine clearance (median) | 103 (IQR 80.5–125.5) | 120 (IQR 71.5–154) | 0.5926 |
| missing | 38 | 41 | |
| Haemoglobin (median) | 12 (IQR 11–13) | 11 (IQR 9–13) | 0.0463 |
| missing | 2 | 8 | |
| Alanine aminotransferase (median) | 18 (IQR 14–24) | 26 (IQR 19–38) |
|
| missing | 11 | 6 | |
| TB status |
| ||
| On TB treatment | 17 | 27 | |
| Screen positive | 0 | 0 | |
| Screened negative | 61 | 30 | |
| Investigation Pending | 1 | 1 | |
| Not Screened | 1 | 11 | |
| Pregnant | 3 | 1 | 0.453 |
| WHO stage |
| ||
| Stage 1 | 42 | 11 | |
| Stage 2 | 11 | 13 | |
| Stage 3 | 22 | 28 | |
| Stage 4 | 5 | 12 | |
| Missing Stage | 0 | 5 |
Nurse Graduate Self-assessment n = 21 n = 21.
| Pre | Post | ||
| mean score | mean score | p-value | |
|
| |||
| Modes of transmission - adults | 3.3 | 3.8 | 0.0083 |
| Modes of transmission - children | 2.905 | 3.737 | 0.0060 |
| Clinical course - adults | 2.619 | 3.7 | 0.0016 |
| Clinical course - children | 2.278 | 3.5 | 0.0004 |
| Signs and symptoms - adults | 3.19 | 3.905 | 0.0014 |
| Signs and symptoms - children | 2.6 | 3.65 | 0.0043 |
| Use of manuals –positive prevention& HIV | 3.25 | 3.75 | 0.0247 |
| Use of Department of Health stationery | 2.8 | 3.789 | 0.0003 |
| Core differences between adults & children | 2.263 | 3.524 | 0.0013 |
|
| |||
| HIV counselling and testing - adults | 3.25 | 3.85 | 0.0008 |
| HIV counselling and testing - children | 2.111 | 3.714 | <0.0001 |
| Diagnosis - adults | 3 | 3.8 | 0.0003 |
| Diagnosis - children | 2 | 3.55 | <0.0001 |
| Staging - adults | 3.3 | 3.905 | 0.0053 |
| Staging - children | 1.8 | 3.619 | <0.0001 |
| Body Mass Index calculation and management | 3.2 | 3.952 | <0.0001 |
| Paediatric weight chart and management | 1.789 | 3.474 | <0.0001 |
| TB screening - adults | 3.476 | 3.857 | 0.1279 |
| TB screening - children | 2.476 | 3.476 | 0.0046 |
| Pap smears and HIV | 2.95 | 3.8 | 0.0007 |
| Common opportunistic infections - adults | 2.952 | 3.762 | 0.0013 |
| Common opportunistic infections - children | 2.1 | 3.381 | 0.0003 |
| TB diagnosis and management - adults | 3.05 | 3.571 | 0.0799 |
| Drug side effects | 2.905 | 3.824 | 0.0187 |
| Cotrimoxazole use - adults | 3.429 | 3.714 | 0.1654 |
| Cotrimoxazole use - children | 2.048 | 3.81 | <0.0001 |
|
| |||
| Eligibility criteria to start - adults | 2.857 | 3.667 | 0.0029 |
| Eligibility criteria to start - children | 1.65 | 3.429 | <0.0001 |
| Fast-tracking criteria | 2.762 | 3.75 | 0.0001 |
| Blood result interpretation - adults | 2.5 | 3.762 | 0.0003 |
| Working withcreatinine clearance | 2.1 | 3.905 | <0.0001 |
| Individual ART contra-indications | 2.35 | 3.81 | 0.0004 |
| Pre-start adherence counseling | 2.55 | 3.7 | 0.0003 |
| Department of Health1st line regimen - adults (ARVs, doses, side effects) | 3 | 3.714 | 0.0870 |
| Department of Health1st line regimen – children (ARVs, doses, side effects) | 1.65 | 3.476 | <0.0001 |
| Prescribing w concurrent illnesses - TB, epilepsy, hypertension, diabetes | 1.857 | 3.75 | <0.0001 |
| Normal course on ARVs | 2.737 | 3.905 | <0.0001 |
| Side effects and their management: | |||
| Skin, haematology, liver, kidney, psychiatric | 2.143 | 3.6 | 0.0010 |
| Recognition of side effects | 2.667 | 3.429 | 0.0530 |
| Understanding IRIS | 2.35 | 3.571 | 0.0031 |
| Long-term side effects | 2.053 | 3.667 | 0.0002 |
| Failing regimen - warning signs | 2.4 | 3.667 | 0.0002 |
| Diagnosis - clinical, immunological, virological | 1.842 | 3.619 | <0.0001 |
| When to refer | 2.333 | 3.857 | <0.0001 |
|
| |||
| Family planning | 3.095 | 3.762 | 0.0012 |
| Wanting to fall pregnant | 2.19 | 3.9 | <0.0001 |
| During pregnancy | 2.571 | 3.7144 | 0.0005 |
| After pregnancy - mother | 2.35 | 3.762 | 0.0003 |
| After pregnancy - child | 2.1 | 3.5 | 0.0006 |
|
| |||
| Non-drug management and administration | 2.05 | 3.762 | <0.0001 |
| Drug regimen and indications | 2.15 | 3.65 | 0.0006 |
|
| |||
| Management of weight loss | 2.7 | 3.571 | 0.0066 |
| Routine clinical examination | 2.438 | 3.667 | 0.0001 |
| Cardiac failure | 1.667 | 3.118 | 0.0005 |
| Enlarged liver | 1.81 | 3.313 | 0.0009 |
| Neck stiffness | 2.15 | 3.5 | 0.0009 |
| Procedures for lactate testing | 1.571 | 3.2 | 0.0001 |
| Understanding the register | 2.111 | 3.167 | 0.0186 |